Patents by Inventor Junichi Mineno

Junichi Mineno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220235375
    Abstract: A method for producing a nucleic acid-encapsulated adeno-associated virus (AAV) hollow particle, comprising the following steps: (1) preparing a linear nucleic acid fragment comprising a sequence for A region and a sequence for D? region in an AAV inverted terminal repeat (ITR) (i.e., an AD sequence) or a sequence complementary to the AD sequence and a target gene sequence; (2) introducing the nucleic acid fragment prepared in step (1) into a cell capable of producing an AAV hollow particle; and (3) culturing the cell obtained in step (2).
    Type: Application
    Filed: July 2, 2020
    Publication date: July 28, 2022
    Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, TAKARA BIO INC.
    Inventors: Takashi OKADA, Junichi MINENO, Hideto CHONO
  • Publication number: 20220162637
    Abstract: The present invention provides a nucleic acid which encodes an adeno-associated virus (AAV) capsid protein mutant that contains a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID Nos. 15 to 62 or a peptide comprising an amino acid sequence produced by substituting, deleting, inserting and/or adding one or several amino acid residues in an amino acid sequence selected from the group consisting of SEQ ID Nos. 15 to 62; DNA comprising the nucleic acid; a cell harboring the DNA; and a method for producing the cell.
    Type: Application
    Filed: April 23, 2020
    Publication date: May 26, 2022
    Applicant: TAKARA BIO INC.
    Inventors: Toshikazu NISHIE, Fuyuko TAKASHIMA, Tatsuji ENOKI, Junichi MINENO, Yoshinori TANAKA
  • Patent number: 11225643
    Abstract: The present invention relates to a method for producing endothelial cells, including carrying out: (a) inducing a population of mesoderm-lineage cells containing endothelial progenitor cells from pluripotent stem cells without forming an embryoid body; and (b) culturing the population of mesoderm-lineage cells containing endothelial progenitor cells in the presence of RepSox, in this order. According to the present invention, endothelial cells with high quality can be efficiently produced from pluripotent stem cells. The endothelial cells obtained by the method of the present invention are useful for the production of, for example, a myocardial sheet, and expected to be utilized in the treatment of a heart disease. A myocardial sheet can be produced by mixing the endothelial cells obtained by the method of the present invention with myocardial cells and mural cells and culturing the cells.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: January 18, 2022
    Assignee: TAKARA BIO INC.
    Inventors: Yuki Yamamoto, Tatsuji Enoki, Yasuhiro Tosaka, Yoko Yamaguchi, Junichi Mineno
  • Publication number: 20210254018
    Abstract: Stem cells can be efficiently proliferated by culturing the stem cells in the presence of a novel recombinant fibronectin fragment.
    Type: Application
    Filed: July 28, 2017
    Publication date: August 19, 2021
    Applicant: TAKARA BIO INC.
    Inventors: Tomomi OTSUJI, Toshikazu NISHIE, Risa KATO, Sachiko OKAMOTO, Tatsuji ENOKI, Junichi MINENO
  • Publication number: 20210246173
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 12, 2021
    Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi OKADA, Hironori OKADA, Hiromi KINOH, Tatsuji ENOKI, Toshikazu NISHIE, Junichi MINENO
  • Patent number: 11028131
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 8, 2021
    Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi Okada, Hironori Okada, Hiromi Kinoh, Tatsuji Enoki, Toshikazu Nishie, Junichi Mineno
  • Publication number: 20210062141
    Abstract: In the present invention, lymphocytes are efficiently grown by culturing lymphocytes in the presence of a novel recombinant fibronectin fragment.
    Type: Application
    Filed: January 24, 2019
    Publication date: March 4, 2021
    Applicant: TAKARA BIO INC.
    Inventors: Tomomi OTSUJI, Yuka HIRASE, Asako HATSUYAMA, Sachiko OKAMOTO, Tatsuji ENOKI, Junichi MINENO
  • Publication number: 20200071675
    Abstract: The present invention relates to a method for producing endothelial cells, including carrying out: (a) inducing a population of mesoderm-lineage cells containing endothelial progenitor cells from pluripotent stem cells without forming an embryoid body; and (b) culturing the population of mesoderm-lineage cells containing endothelial progenitor cells in the presence of RepSox, in this order. According to the present invention, endothelial cells with high quality can be efficiently produced from pluripotent stem cells. The endothelial cells obtained by the method of the present invention are useful for the production of, for example, a myocardial sheet, and expected to be utilized in the treatment of a heart disease. A myocardial sheet can be produced by mixing the endothelial cells obtained by the method of the present invention with myocardial cells and mural cells and culturing the cells.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 5, 2020
    Applicant: TAKARA BIO INC.
    Inventors: Yuki YAMAMOTO, Tatsuji ENOKI, Yasuhiro TOSAKA, Yoko YAMAGUCHI, Junichi MINENO
  • Publication number: 20200002384
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Application
    Filed: January 29, 2018
    Publication date: January 2, 2020
    Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi OKADA, Hironori OKADA, Hiromi KINOH, Tatsuji ENOKI, Toshikazu NISHIE, Junichi MINENO
  • Publication number: 20180362933
    Abstract: The present invention produces a large number of mesenchymal stem cells in a short time in a medium containing no heterologous components by including a step for culturing a cell population containing mesenchymal stem cells in the presence of a fibronectin fragment.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 20, 2018
    Applicant: TAKARA BIO INC.
    Inventors: Kenichi TAHARA, Ikuei NUKAYA, Mitsuko IDENO, Saori YAMAGUCHI, Junichi MINENO
  • Patent number: 10072250
    Abstract: The present invention provides a method for efficiently manufacturing a non-enveloped virus with high purity without laborious operation by cultivating cells having the ability to produce a non-enveloped virus and bringing the cells and an acidic solution into contact with each other. A non-enveloped virus vector manufactured by the method of the present invention and a composition having the non-enveloped viral vector as an active ingredient are very useful as gene transfer methods in the fields of basic research and clinical application gene therapy.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: September 11, 2018
    Assignee: TAKARA BIO INC.
    Inventors: Shuhei Sakamoto, Yasuhiro Kawano, Katsuyuki Dodo, Tatsuji Enoki, Hirofumi Yoshioka, Hikaru Takakura, Junichi Mineno
  • Patent number: 10023846
    Abstract: Provided are a production method for non-enveloped virus particles which is characterized in that a sample including non-envelopes virus particles is treated with PEG in at least two concentrations; a kit used in said production method; non-enveloped virus particles produced using said production method; and a pharmaceutical composition having the non-envelopes virus particles as an active ingredient.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: July 17, 2018
    Assignee: TAKARA BIO INC.
    Inventors: Toshikazu Nishie, Yasuhiro Kawano, Shuhei Sakamoto, Tatsuji Enoki, Hikaru Takakura, Junichi Mineno
  • Patent number: 9938541
    Abstract: The invention provides an AAV particle containing an adeno-associated viral (AAV) capsid protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30 of the sequence listing; a nucleic acid that encodes this capsid protein; DNA containing this nucleic acid; a cell containing this DNA; and a method for producing this cell.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 10, 2018
    Assignee: TAKARA BIO INC.
    Inventors: Toshikazu Nishie, Fuyuko Takashima, Tatsuji Enoki, Junichi Mineno
  • Patent number: 9850498
    Abstract: The present invention provides an expression cassette comprising (1) an expression regulatory region having a sequence corresponding to a transcriptional activator-binding region and (2) a nucleic acid encoding a transcriptional activator which is capable of binding to the expression regulatory region, wherein the nucleic acid is operably linked to the expression regulatory region; a method for expressing a target product in a mammalian cell, a method for producing a cell expressing a target product, and a method for producing a target product in a mammalian cell using the expression cassette; and a kit comprising the expression cassette.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: December 26, 2017
    Assignee: TAKARA BIO INC.
    Inventors: Katsuyuki Dodo, Takahisa Tsukihara, Mayumi Shimomura, Koichi Inoue, Hideto Chono, Junichi Mineno, Masanari Kitagawa
  • Patent number: 9822380
    Abstract: A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene can be regulated by the transcription regulation sequence; a method for production of a cell showing an inhibited replication of a human immunodeficiency virus therein, the method comprising the step of introducing the nucleic acid into a cell; and a method for treatment or prevention of a human immunodeficiency virus infection.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: November 21, 2017
    Assignee: TAKARA BIO INC.
    Inventors: Hideto Chono, Kazuya Matsumoto, Junichi Mineno, Ikunoshin Kato
  • Publication number: 20170166871
    Abstract: Provided are a production method for non-enveloped virus particles which is characterized in that a sample including non-envelopes virus particles is treated with PEG in at least two concentrations; a kit used in said production method; non-enveloped virus particles produced using said production method; and a pharmaceutical composition having the non-envelopes virus particles as an active ingredient.
    Type: Application
    Filed: July 9, 2015
    Publication date: June 15, 2017
    Applicant: TAKARA BIO INC.
    Inventors: Toshikazu NISHIE, Yasuhiro KAWANO, Shuhei SAKAMOTO, Tatsuji ENOKI, Hikaru TAKAKURA, Junichi MINENO
  • Patent number: 9670459
    Abstract: The present invention addresses the problem of providing cell populations having a high proportion of CD4-positive naive T cells and/or CD4-positive central memory T cells, and a production method thereof. The present invention provides a production method for CD4-positive T cell populations which is characterized by using anti-CD3 antibodies, fibronectin fragments, and Interleukin-4. The method is characterized not only by the attainment of a cell group with a high proportion of CD4-positive naive T cells and/or CD4-positive central memory T cells, but also by a high bulk yield.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: June 6, 2017
    Assignee: TAKARA BIO INC.
    Inventors: Katsuyuki Dodo, Hideto Chono, Junichi Mineno
  • Patent number: 9603874
    Abstract: Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 28, 2017
    Assignees: Takara Bio Inc., Mie University
    Inventors: Hiroshi Shiku, Hiroaki Ikeda, Koichi Iwamura, Junichi Mineno, Ikunoshin Kato
  • Patent number: 9422576
    Abstract: According to the present invention, an AAV vector having a higher titer compared with those of conventional ones can be produced using a cell into which a nucleic acid capable of expressing miRNA is introduced artificially. An AAV vector produced using the cell and a composition containing the viral vector as an active ingredient are very useful as gene transfer means in the studies or clinical practice of gene therapies.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: August 23, 2016
    Assignee: TAKARA BIO INC.
    Inventors: Toshikazu Nishie, Fuyuko Takashima, Tatsuji Enoki, Junichi Mineno
  • Patent number: 9399780
    Abstract: The present invention provides a method for producing a virus vector, which involves a step of culturing a cell capable of producing the virus vector in a culture medium containing a retinoic acid compound, a histone deacetylase-inhibiting substance and a substance capable of forming a chelate; and a culture medium for use in the production of a virus vector, which is characterized by containing a retinoic acid compound, a histone deacetylase-inhibiting substance and a substance capable of forming a chelate as active ingredients.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 26, 2016
    Assignee: TAKARA BIO INC.
    Inventors: Kazuhisa Shinmura, Hirofumi Yoshioka, Hikaru Takakura, Junichi Mineno